Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 23;14(1):16899.
doi: 10.1038/s41598-024-67795-z.

Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy

Zhendong Shi  1   2   3   4 , Yingxue Liu  1   2   3   4 , Xuan Fang  1   2   3   4 , Xu Liu  1   2   3   4 , Jie Meng  1   2   3   4 , Jin Zhang  5   6   7   8
Affiliations

Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy

Zhendong Shi et al. Sci Rep. .

Abstract

Mounting evidence showed that HER2-Low breast cancer patients could benefit from the novel anti-HER2 antibody-drug conjugates (ADCs) treatment, which pointed the way towards better therapy for HER2-Low patients. The purpose of this study was to describe the clinicopathological features, along with chemotherapeutic effects and survival outcomes of HER2-Low and HER2-Zero in TNBC who received neoadjuvant chemotherapy (NACT). We retrospectively evaluated 638 triple-negative breast cancer patients who were treated with neoadjuvant chemotherapy between August 2014 and August 2022. Pathologic complete response (pCR) and survival outcomes were analyzed in HER2-Low cohort, HER2-Zero cohort and the overall patients, respectively. In the entire cohort, 342 (53.6%) patients were HER2-Low and 296 (46.4%) patients were HER2-Zero. No significant difference was found between HER2-Low and HER2-Zero patients based on all the clinical-pathological characteristics. 143 cases (22.4%) achieved pCR after NACT in the overall TNBC patients. The pCR rate of the HER2-Low patients and the HER2-Zero patients was 21.3% and 23.6%, respectively, exhibiting no statistical difference (p = 0.487). The survival of pCR group after NACT significantly improved compared to non-pCR group either in HER2-Low patients or in HER2-Zero patients. Although we found that patients with HER2-Low had longer DFS than patients with HER2-Zero, there was no considerable difference (p = 0.068). However, HER2-Low patients had a dramatically longer OS than HER2-Zero patients (p = 0.012). The data from present study confirmed the clinical importance of HER2-Low expression in TNBC. Further effort is needed to determine whether HER2-Low could be a more favorable prognostic marker for individual treatment.

Keywords: Disease free survival; HER2-Low; Neoadjuvant chemotherapy; Overall survival; Pathologic complete response; Triple-negative breast cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
PCR rate in overall patients, HER2-Low group and HER2-Zero group (A). Forest plots for multivariable logistic regression analysis of pCR rates for HER2-low group (B), HER2-Zero group (C) and the overall patients (D).
Figure 2
Figure 2
Kaplan–Meier survival analysis for DFS and OS between pCR and non-pCR in HER2-Low group (A,B), HER-2 Zero group (C,D) and overall patients (E,F).
Figure 3
Figure 3
Kaplan–Meier survival analysis for DFS (A) and OS (B) between HER2-Low and HER-Zero group.
See this image and copyright information in PMC

References

    1. Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2021. CA Cancer J. Clin.71(1), 7–33 (2021). 10.3322/caac.21654 - DOI - PubMed
    1. Palma, G. et al. Triple negative breast cancer: Looking for the missing link between biology and treatments. Oncotarget.6(29), 26560–26574 (2015). 10.18632/oncotarget.5306 - DOI - PMC - PubMed
    1. Zheng, Y. Z., Liu, Y., Deng, Z. H., Liu, G. W. & Xie, N. Determining prognostic factors and optimal surgical intervention for early-onset triple-negative breast cancer. Front. Oncol.12, 910765 (2022). 10.3389/fonc.2022.910765 - DOI - PMC - PubMed
    1. Boyle, P. Triple-negative breast cancer: Epidemiological considerations and recommendations. Ann. Oncol.23(Suppl 6), 7–12 (2012). 10.1093/annonc/mds187 - DOI - PubMed
    1. Morris, G. J. et al. Differences in breast carcinoma characteristics in newly diagnosed African–American and Caucasian patients: A single-institution compilation compared with the National Cancer Institute’s Surveillance, Epidemiology, and End Results database. Cancer.110(4), 876–884 (2007). 10.1002/cncr.22836 - DOI - PubMed

MeSH terms

LinkOut - more resources